The global anti-microbial/anti-fungal tests market is expected to reach USD 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~USD 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.
| Attributes | Key Insights |
|---|---|
| Anti-microbial/Anti-fungal Tests Market Value 2021 | USD 2.4 Billion |
| Estimated Market Size 2022 | USD 2.5 Billion |
| Projected Market Value 2032 | USD 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Market Share of Top 5 Countries | 55.0% |
Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.
Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~USD 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.
Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.
As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.
The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.
Favorable Government Initiatives and Awareness Programs to Fuel the Growth
Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.
Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.
Principal Consultant
The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.
Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.
Growing Preference for Diagnostic Tests to Boost the Sales
The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.
Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China
China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.
Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.
It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.
Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection
Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.
This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond
Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.
Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.
Nearly 2 out of 5 Sales are Contributed by Hospitals
As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.
With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
| Attribute | Details |
|---|---|
| Estimated Market Size 2022 | USD 2.5 Billion |
| Projected Market Value 2032 | USD 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa |
| Key Market Segments Covered | Tests, Infection, End User, and Region |
| Key Companies Profiled | Abbott Laboratories; bioMérieux SA; Bio-Rad Laboratories Inc; Bruker Corporation; Danaher Corporation; Erba Mannheim; F. Hoffmann-La Roche AG; Luminex Corporation; Meridian Bioscience Inc; Norgen Biotek Corp; Omega Diagnostics Group Plc; Qiagen N.V; Quidel Corporation; Thermo Fisher Scientific Inc |
The global anti-microbial/anti-fungal tests market is worth USD 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.
The anti-microbial/anti-fungal tests market is expected to reach USD 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.
The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.
USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.
North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.
Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.
Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.
China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.
Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type 7.1. Molecular-Based Tests 7.1.1. PCR Test 7.1.2. DNA Microarray 7.2. Phenotypic Resistance Tests 7.3. Complex Test Panels 7.4. Mass Spectrometry 7.5. Rapid Diagnostic Tests 7.5.1. E-Test Antibiotic/Antifungal Strips 7.5.2. Biosensor Platforms 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type 8.1. Antimicrobial Resistance 8.1.1. Methicillin-Resistant Staphylococcus Aureus 8.1.2. Vancomycin-Resistant Enterococcus 8.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis 8.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria 8.2. Microbial Infection 8.3. Antifungal Resistance 8.3.1. Candida infections 8.3.2. Aspergillus infection 8.3.3. Fusariosis 8.3.4. Others 8.4. Fungal Infection 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 9.1. Hospitals 9.2. Ambulatory Surgical Centers 9.3. Clinics 9.4. Community Health Centers 9.5. Reference Laboratories 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. Middle East and Africa (MEA) 11. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16. Oceania Market 2017 to 2021 and Forecast 2022 to 2032 17. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18. Market Structure Analysis 19. Competition Analysis 19.1. Abbott Laboratories 19.2. bioMérieux SA 19.3. Bio-Rad Laboratories Inc. 19.4. Bruker Corporation 19.5. Danaher Corporation 19.6. Erba Mannheim 19.7. F. Hoffmann-La Roche AG 19.8. Luminex Corporation 19.9. Meridian Bioscience Inc. 19.10. Norgen Biotek Corp. 19.11. Omega Diagnostics Group Plc. 19.12. Qiagen N.V. 19.13. Quidel Corporation 19.14. Thermo Fisher Scientific Inc. 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Anti-microbial/Anti-fungal Tests Market
